NLSP News and Press, NLS Pharmaceutics Ltd. From 12/01/23

2023-12-01 08:22:37 ET DENVER, Colo., Dec 1, 2023 ( www.247marketnews.com )- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) announced, this morning, that it entered into an exclusive worldwide option agreement with Aexon Labs, under which NLS may acquire global development and commercialization ...

The option agreement grants NLS Pharmaceutics Ltd. the exclusive option to in-license all of Aexon Labs' assets for the potential treatment of narcolepsy and other neuro-degenerative disorders, and all future indications Exclusive option agreement accesses global rights to multiple highly se...

Professor Claudio L. A. Bassetti, MD, is the Chair, Neurology Department, Inselspital, Bern University Hospital and Dean, Medical Faculty, University of Bern, focused on sleep disorders Professor Florence Allouche Aknin, PharmD, MBA, is a professor at University Paris City, specializing in p...

ZURICH, SWITZERLAND / ACCESSWIRE / November 27, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system...

NLS has executed a non-binding term sheet for licensing of NLS intellectual property NLS has secured an additional bridge loan through insiders to extend cash runway NLS has implemented significant internal cost reductions ZURICH, SWITZERLAND / ACCESSWIRE / November 16, 2023 / NLS...

2023-10-25 16:50:50 ET More on NLS Pharmaceutics Seeking Alpha’s Quant Rating on NLS Pharmaceutics Historical earnings data for NLS Pharmaceutics Financial information for NLS Pharmaceutics For further details see: NLS Pharmaceutics announces recei...

ZURICH, SWITZERLAND / ACCESSWIRE / October 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system ...

Members of Executive Leadership Team to Discuss Company Update on Strategic Discussions and Timeline of Phase 3, NLS to Webcast its Event Friday, October 20 at 11:00am ET ZURICH, SWITZERLAND / ACCESSWIRE / October 12, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or ...

2023-08-31 08:26:12 ET Prime Number Acquisition  ( NCNC ) +39% . Allarity Therapeutics ( ALLR ) +35% . iCoreConnect ( ICCT ) +34% . NLS Pharmaceutics ( NLSP ) +19% . Tingo Group ( TIO ) +14% Reports Second Quarter 2023 Financi...

2023-07-27 08:38:02 ET Mersana Therapeutics ( MRSN ) -74% announces topline data from UPLIFT clinical trial in patients with platinum-resistant Ovarian Cancer and strategic reprioritization. Biohaven ( BHVN ) -27% . Yellow Corporation ( YELL ) -26% . ...